From Polish Biosimilars to Building a Biologics CDMO

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development and commercialisation lifecycle with Dr Adriana Kiedzierska-Mencfeld, CEO of Rezon Bio.

Adriana Kiędzierska-Mencfeld is the CEO of Rezon Bio, where she leads the company’s strategy, operations and partnerships across biologics development and manufacturing. With more than 20 years of experience in biotechnology, she specialises in recombinant proteins, purification and biosimilars.

Previously, she held senior roles at Polpharma Biologics, including COO and Site Head, where she helped support the transition to commercial scale manufacturing and contributed to FDA and EMA approvals. Adriana holds a PhD from the University of Wrocław and an Executive MBA from IMD, combining deep technical expertise with strategic leadership.

Your host, Raman Sehgal, discusses the pharma and biopharma ecosystem with Adriana, covering:

• How her personal story led her into science and biologics, and onto the path of helping build a biopharma hub in Poland
• How each stage of her career taught her something different, and why CEOs should create the conditions for people to achieve more
• The importance of purpose, values and doing work that is genuinely meaningful for patients
• The journey from legacy biosimilars to bringing the first Polish manufactured biologic to the global market, and ultimately into the CDMO world
• The mindset and culture shift required when moving from an established biologics organisation to a genuinely client centric CDMO business
• How Rezon Bio is positioning itself for the future around pricing, added value, partnerships and the growing importance of dual sourcing

Connect with her on LinkedIn. 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!